Mental Health Relief

Posted on by

FDA Approves Ketamine Nasal Spray for Suicidal Thoughts and Severe Depression

On Tuesday,March 5th 2019 the U.S. Food and Drug Administration (FDA) approved the ketamine-based nasal spray esketamine (brand name Spravato) for treating severe depression and persistent suicidal thoughts. The drug, which was developed by Janssen Research & Development, is the first major mental health drug treatment breakthrough in decades.
Esketamine — a “chemical cousin” to ketamine — works on the brain similarly to existing antidepressants. Instead of taking weeks to have an effect however, ketamine-based drugs have been shown to work almost immediately, which provides much faster relief for those with severe depression.
If you have any reason to find help Text HOME to 686868 in Canada to text with a trained Crisis Responder. 

Leave a Reply

Your email address will not be published. Required fields are marked *